• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
BKM120

BKM120

Product ID B4248
Cas No. 944396-07-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $82.00 In stock
5 mg $228.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

BKM120 is an inhibitor of PI3K that is currently in clinical trials as a potential treatment for brain metastases of HER2+ breast cancer and other solid tumors. BKM120 exhibits anticancer chemotherapeutic and anti-metastatic activities, inducing G2/M phase cell cycle arrest, polyploidy, and apoptosis in glioblastoma cells. Additionally, BKM120 decreases levels of Mcl-1 and enhances TRAIL-dependent apoptosis in lung cancer cells. BKM120 also binds tubulin, inhibiting microtubule polymerization. This compound prevents invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

944396-07-0

Purity

≥98%

Formula

C18H21F3N6O2

Formula Wt.

410.39

IUPAC Name

5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine

Synonym

Buparlisib, NVP-BKM120

Solubility

DMSO 82 mg/mL (199.8 mM) Ethanol 2 mg/mL (4.87 mM) Water Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

B4248 MSDS PDF

Info Sheet

B4248 Info Sheet PDF

Brochures

PI3K-Akt-mTORC Pathway Booklet

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Wachsberger PR, Lawrence YR, Liu Y, et al. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol. 2014 Feb 6. [Epub ahead of print]. PMID: 24500492.

Ando Y, Inada-Inoue M, Mitsuma A, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci. 2014 Jan 10. [Epub ahead of print]. PMID: 24405565.

Ren H, Zhao L, Li Y, et al. The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Lett. 2013 Sep 28;338(2):229-38. PMID: 23562472.

Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012 Aug;11(8):1747-57. PMID: 22653967.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • O5212

    Ondansetron Hydrochloride Dihydrate

    5-HT3 antagonist.

    ≥98%
  • K1679

    (+)-Ketanserin Tartrate

    5-HT2A and TRPV1 antagonist, potential α1-adre...

    ≥98%
  • A4646

    ALLN

    Calpain I/II inhibitor.

    ≥98%
  • P2857

    Phorbol-12-myristate-13-acetate

    PKC activator, carcinogen.

    ≥98%
  • T0096

    Cephalomannine

    Diterpene found in Taxus; potential microtubule...

    ≥98%
  • B177550

    Benzbromarone

    Non-competitive inhibitor of xanthine oxidase.<...

    ≥99%
  • C577524

    Concanamycin A

    Macrolide lactone antibiotic.

    ≥98%
  • F0275

    Fasudil Hydrochloride

    ROCK inhibitor.

    ≥98%
  • A9812

    AZD-1480

    JAK1/2 inhibitor.

    ≥98%
  • V1810

    Vecuronium Bromide

    Non-depolarizing NMJ blocker; nAChR antagonist....

    ≥98%
  • V3212

    Vidarabine

    Nucleoside (adenosine) analog; viral DNA polyme...

    ≥98%
  • L493400

    LMK-235

    Selective HDAC4 and HDAC5 inhibitor.

    ≥98%
  • T0394

    (+)-Taxifolin

    Catechol-type flavonoid; fatty acid synthesis i...

    ≥98%
  • D5612

    2-n-Dodecylfuran

    Furan derivative.

    ≥98%
  • P6801

    Pravastatin Sodium

    Statin; HMG-CoA reductase inhibitor.

    ≥98%
  • P2859

    Phosphate Acceptor Peptide

    PKC and S6 kinase substrate.

    ≥95%
  • C4758

    Closantel Sodium

    Protonophore; chitinase OvCHT1 inhibitor.

    ≥98%
  • P9671

    Pyrazinamide

    Nicotinamide analog prodrug; fatty acid synthet...

    ≥98%
  • I0902

    Icaritin

    Flavonoid found in Epimedium.

    ≥98%
  • D0255

    Dantrolene Sodium Heptahydrate

    Hydantoin derivative; RyR antagonist, L-type Ca...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only